Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA), today announced that Genospace, LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
Sarah Cannon and Genospace, LLC Announce Merger to Enhance Cancer Care Through Personalized Medicine Platform
ACLA Warns CMS’ Proposed Coding and Payment Proposals that Pose Draconian Cuts to Innovative Life-Saving Diagnostics Will Jeopardize the Advancement of Personalized Medicine
The nation’s largest organization representing the public policy interests of clinical laboratories across the U.S., the American Clinical Laboratory Association (ACLA), said today coding and payment proposals for highly advanced molecular diagnostic tests recently released by the Centers for Medicare and Medicaid (CMS) will seriously hamstring physicians’ ability to determine the best course of treatment and impact patient care for those depending on accurate diagnoses and effective medications.
Sanguine, a leading technology company providing services to the personalized medicine and biomedical research market, recently announced that they will be expanding their services to improve clinical trial efficiency through enhanced patient recruitment, retention and trial procedures. Sanguine, which primarily operated in the pre-clinical space until now, will be fulfilling a big need in later stage clinical development through a combination of their smart technology and adaptable mobile health force.
The Swedish Cancer Institute (SCI), one of the Northwest’s leading cancer treatment centers, recently announced the adoption of Syapse Precision Medicine Platform to enhance its Personalized Medicine Program. The innovative software platform will enable clinicians to better integrate genomic information into patient care and move critical cancer research forward.
New Study Shows Cleveland HeartLab Inflammation Testing can Prevent Thousands of Heart Attacks and Strokes, Averting $187 Million in Healthcare Costs for Cardiovascular Disease
Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease management company, and MDVIP, the leader in personalized, preventive medicine, are pleased to announce the publication of a seminal peer review study in the Journal of Medical Economics. The study shows that by improving cardiovascular disease risk (CVD) assessment, CHL’s inflammation testing could reduce heart attacks and strokes by nearly 10 percent.